Global Glucagon-like Peptide-1 Receptor Agonist Market Growth (Status and Outlook) 2025-2031

According to this study, the global Glucagon-like Peptide-1 Receptor Agonist market size will reach US$ 26360 million by 2031.

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

LPI (LP Information)' newest research report, the “Glucagon-like Peptide-1 Receptor Agonist Industry Forecast” looks at past sales and reviews total world Glucagon-like Peptide-1 Receptor Agonist sales in 2024, providing a comprehensive analysis by region and market sector of projected Glucagon-like Peptide-1 Receptor Agonist sales for 2025 through 2031. With Glucagon-like Peptide-1 Receptor Agonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Glucagon-like Peptide-1 Receptor Agonist industry.

This Insight Report provides a comprehensive analysis of the global Glucagon-like Peptide-1 Receptor Agonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Glucagon-like Peptide-1 Receptor Agonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Glucagon-like Peptide-1 Receptor Agonist market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Glucagon-like Peptide-1 Receptor Agonist and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Glucagon-like Peptide-1 Receptor Agonist.

This report presents a comprehensive overview, market shares, and growth opportunities of Glucagon-like Peptide-1 Receptor Agonist market by product type, application, key players and key regions and countries.

Segmentation by Type:
Exenatide
Liraglutide
Lixisenatide
Albiglutide
Others

Segmentation by Application:
Solid Tumors
Blood-related Tumors

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GSK
Novo Nordisk
Lily
Haosoh
Sanofi
AstraZeneca

Please note: The report will take approximately 2 business days to prepare and deliver. Show more